Thursday, January 11, 2018 10:15 PM ET
Significant Insider buy of CRISPR Therapeutics (CRSP) Shares Reverses Selling Trend of Last Quarter
Significant insider buying activity was disclosed in CRISPR Therapeutics shares in a form 4 document filed with the SEC today, showing — Kurt von Emster, Director — acquired 65,934 shares in the company having a net market value of approximately $1,499,999. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 1,305,219 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 1,239,285 shares and have averaged 228,526 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at CRISPR Therapeutics is greater than its 191-company peer group average. The Biotechnology & Medical Research peer group saw 159 buy/sell trades during this period for an average of 0.8 transactions per company. However, the number of shares traded per transaction by CRISPR Therapeutics insiders is lower than its peers. Within the peer group there were 26,385,061 shares purchased and 11,107,168 shares sold with company insiders having bought 131,706 shares on average over this time period.
The data obtained in creating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.